Ampio Pharmaceuticals (NYSE:AMPE) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Shares of AMPE stock opened at $0.50 on Friday. Ampio Pharmaceuticals has a 52 week low of $0.14 and a 52 week high of $8.30. The stock has a market capitalization of $565,519.80, a PE ratio of -0.05 and a beta of 1.95. The stock’s fifty day moving average is $1.33 and its 200-day moving average is $1.97.

Ampio Pharmaceuticals (NYSE:AMPE) last issued its quarterly earnings results on Wednesday, March 27th. The company reported ($2.48) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Ampio Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Ampio Pharmaceuticals by 0.4% in the first quarter. BlackRock Inc. now owns 13,996,074 shares of the company’s stock valued at $6,578,000 after buying an additional 61,269 shares during the period. State Street Corp lifted its stake in Ampio Pharmaceuticals by 2.0% in the first quarter. State Street Corp now owns 3,430,770 shares of the company’s stock valued at $1,612,000 after buying an additional 66,375 shares during the period. Vanguard Group Inc. lifted its stake in Ampio Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 9,307,338 shares of the company’s stock valued at $4,375,000 after buying an additional 77,822 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Ampio Pharmaceuticals by 73.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the company’s stock valued at $66,000 after buying an additional 166,979 shares during the period. Finally, HRT Financial LP raised its position in shares of Ampio Pharmaceuticals by 1,399.2% during the first quarter. HRT Financial LP now owns 217,052 shares of the company’s stock worth $50,000 after purchasing an additional 202,574 shares during the period. Institutional investors and hedge funds own 5.73% of the company’s stock.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.